Philadelphia, PA, United States of America

Ryan Eberwine


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovator Spotlight: Ryan Eberwine

Introduction: Ryan Eberwine is an accomplished inventor based in Philadelphia, Pennsylvania. With a keen focus on medical advancements, he has made significant contributions to the field of biotechnology. His work, particularly in developing antibodies, showcases his innovative spirit and dedication to improving healthcare.

Latest Patents: Eberwine holds a patent for "Anti-HLA-C antibodies and uses thereof." This patent outlines the development of Anti-HLA-C6 antibodies and antigen-binding fragments. It also includes nucleic acids encoding the antibodies, compositions that utilize these antibodies, and methods for producing them. Importantly, the patent discusses applications for treating or preventing diseases, including various autoimmune disorders, emphasizing the potential of his work in therapeutic settings.

Career Highlights: Ryan Eberwine is currently employed at Janssen Biotech, Inc., a prominent company known for its contributions to pharmaceuticals and biotechnology. His work there has positioned him at the forefront of innovative biomedical research.

Collaborations: Throughout his career, Eberwine has collaborated with colleagues such as Anne Fourie and Paul H Kim. These partnerships highlight his ability to work effectively in team environments, fostering an exchange of ideas that contributes to the advancement of their projects.

Conclusion: Ryan Eberwine exemplifies the qualities of an innovative inventor, bringing new solutions to the healthcare industry through his patented work. His contributions not only reflect his expertise but also hold promise for future developments in medical treatments. As he continues to collaborate with talented professionals, Eberwine’s impact on biotechnology will undoubtedly grow, benefiting countless individuals in need of effective therapeutic options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…